Researcher Daan van der Vliet, together with colleagues from the Netherlands Institute for Neuroscience, Leiden University and Utrecht University, has discovered an important mechanism that may be linked to severe cases of multiple sclerosis (MS): the brain contains large numbers of abnormal immune…

How do you know if a drug will actually work? The Leiden-based spin-off Omivera is developing a new technology that could provide clearer answers. The young company received a seed investment from the investment fund UNIIQ to support its development.

Mini organs-on-chips allow us to study how diseases develop and how drugs work. Although the technology is not new, it is becoming increasingly advanced. PhD candidate Bart Kramer hopes it will eliminate animal testing in the future.

Two consortia led by Leiden researchers have been awarded over one million euros by the Dutch Research Council and the Ministry of Health, Welfare and Sport to find solutions to antimicrobial resistance.

The antibiotic EVG7, developed in Leiden, has proven capable of fighting the dangerous gut bacterium C. difficile with only a minimal dose. What’s more, the bacterium is far less likely to return, a major issue with existing antibiotics. The research was published in Nature Communications.

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

Bacteria carry countless hidden treasures in their DNA: fragments that could hold the key to new medicines. But how do you pick out the most promising ones from millions of options? ‘Look at the switches that turn genes on and off,’ says molecular biologist Gilles van Wezel.

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

Before patients can take a pill, scientists often spend years in the lab developing and testing a candidate drug. That often includes experiments with laboratory animals. As head of the rodent facility, Ilze Bot and her colleagues ensure that these experiments are conducted in an ethically responsible…

Not experiments and lab coats, but computers and artificial intelligence: this year's Nobel Prize in Chemistry went to the inventors of the groundbreaking AI model, AlphaFold. This programme accurately predicts protein structures based on their genetic code—a crucial step in understanding biological…